Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Eli Lilly (NY: LLY )

748.01 -1.91 (-0.25%)
Official Closing Price Updated: 4:10 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
99 100 Next >
Analyzing Eli Lilly and Co In Comparison To Competitors In Pharmaceuticals Industry
Via Benzinga
Stock Market Diverges, With Tesla, Google, ServiceNow, GE In Focus: Weekly Review
Small caps continued to lead, while the Nasdaq broke below key levels. 
Via Investor's Business Daily
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
The European Medicines Agency's CHMP has rejected the approval of Eisai and Biogen's Alzheimer's treatment lecanemab, citing concerns over its risks. Eisai plans to appeal the decision and work towards... 
Via Benzinga
Expert Outlook: Eli Lilly and Co Through The Eyes Of 25 Analysts
Via Benzinga
Market Whales and Their Recent Bets on LLY Options
Via Benzinga
Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug
Biogen partner Eisai is planning to ask European regulators to re-examine their decision. 
Via Investor's Business Daily
Prediction: This Is What Eli Lilly Stock Will Do Next
Shares of Eli Lilly are up more than 130% in the past year, but this company's moves are far from finished. 
Via The Motley Fool
Walt Disney, Eli Lilly, AST SpaceMobile, DexCom, Tesla: Why These 5 Stocks Are On Investors' Radars Today
On Thursday, major U.S. indices showed mixed results. The Dow Jones Industrial Average increased by 0.2% to 39,935.07. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
Companies like Novo Nordisk and Eli Lilly might soon have a determined competitor in their hottest product category. 
Via The Motley Fool
7 Explosive Growth Stocks Set to Soar in 2024
These seven explosive growth stocks across various sectors have the potential to deliver substantial returns for investors in 2024. 
Via InvestorPlace
Novo Nordisk Shares Decline Amid Competitive Pressure
Novo Nordisk A/S Common Stock (NYSE: NVO) experienced a notable decline on Thursday. This movement follows a significant announcement from competitor Viking Therapeutics Inc. (NASDAQ:VKTX). 
Via Benzinga
3 Top-Performing Stocks Beating the Big Names in 2024
The following top-performing stocks may continue to gain as the Magnificent Seven runs out of steam in July. 
Via InvestorPlace
Viking Therapeutics Stock Surges As Company Advances Weight Loss Drug To Late-Stage Trial: What Investors Need To Know
Viking Therapeutics Inc (NASDAQ:VKTX) shares are rising Thursday after the biotech company announced plans to advance its experimental weight loss drug to late-stage trials. 
Via Benzinga
Why Eli Lilly and Company Shares Are Moving Lower On Thursday
Eli Lilly and Company stock is trading lower on Thursday after Viking Therapeutics announced the advancement of its novel treatment for obesity, VK2735. 
Via Benzinga
3 Companies Gearing Up for a Stock Split
These stock split candidates could follow the route of Nvidia, Walmart and Chipotle Mexican Green in the near future. 
Via InvestorPlace
Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 15 Years
Via Benzinga
Viking Therapeutics Unveils Monthly Weight-Loss Shot, And Rocks Eli Lilly, Novo Nordisk
Viking Therapeutics stock rocketed Thursday after the company said it's exploring a monthly dose of its weight-loss drug. 
Via Investor's Business Daily
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
From FN Media Group LLC
Via GlobeNewswire
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it. 
Via InvestorPlace
Elon Musk Agrees With Former Executive Who Thinks 'Everyone' Has 'Strong' Opinions On Tesla Unlike In The Case Of Eli Lilly And LVMH
Investors have strong opinions on Tesla but not on LVMH or Eli Lilly, Musk agrees on Twitter. Tesla's controversial CEO and recent financial struggles may explain heightened interest. 
Via Benzinga
3 Fabulous Growth Stocks to Buy and Hold Forever
The bull market in growth stocks is more than just chipmakers if investors will only widen their lens to see the opportunities available. 
Via InvestorPlace
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
Wegovy, a GLP-1 receptor agonist, had previously been approved for use in obesity treatment and weight management. 
Via Benzinga
3 Dividend Growth Stocks That Have Doubled Their Payouts in 5 Years
Their yields may seem low, but these stocks have been growing their dividend payments at a fast pace. 
Via The Motley Fool
If You'd Invested $10,000 in Eli Lilly Stock 5 Years Ago, Here's How Much You'd Have Today
Could today's momentum continue? 
Via The Motley Fool
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
Roche might give Lilly and Novo Nordisk a run for their money -- sometime down the road. 
Via The Motley Fool
Don’t Delay! 3 Stocks to Buy BEFORE Q2 Earnings.
These stocks to buy before earnings are likely to jump higher after the companies behind them report their Q2 financial results. 
Via InvestorPlace
Biden's Exit From Presidential Race 'Yet Another Curveball For Equity Investors': Analysts
President Biden's decision to drop out may harm healthcare and create market volatility. Kamala Harris could defend his record and support Medicare for All. 
Via Benzinga
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
HC Wainwright initiated coverage on AnaptysBio with a Buy rating and a $55 price target. AnaptysBio focuses on immunology therapeutics with a promising pipeline. 
Via Benzinga
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
Pharmaceutical giants like Roche, Eli Lilly, Novo Nordisk, and Pfizer are racing to develop oral weight loss medications. These drugs promise to complement existing injectables, offering new hope in... 
Via Benzinga
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.